← Back to headlines
Eli Lilly Acquires Merida Biosciences in Nearly $3 Billion Cash Deal
Pharmaceutical giant Eli Lilly has agreed to acquire autoimmune-focused biotech firm Merida Biosciences in an all-cash transaction valued at up to $2.9 billion. The acquisition expands Lilly’s pipeline in inflammatory and immune-mediated diseases.
31 Aug, 10:48 — 31 Aug, 11:23
The Story
Analyzing sources…
Source Diversity
Source Diversity
High (51/100)4 sources30/33
Spectrum spread— 3/5 buckets covered17/33
Far L
Left1
Left (1)
cnbc
Center1
Center (1)
investing-com
Right2
Right (2)
Barron'sseeking-alpha
Far R
Geographic diversity— 1 region4/34
US4
ℹAll sources from US region
Sources
Showing 4 of 4 sources
cnbcMostly Factual1h ago
Eli Lilly to buy Merida Biosciences in deal worth up to $2.88 billion
Eli Lilly plans to buy privately held Merida Biosciences for up to $2.88 billion in cash.
Read full article →Barron'sHigh1h ago
Lilly to Buy This Autoimmune Drugmaker for $2.9 Billion in Cash. What It Means for the Stock. - Barron's
Lilly to Buy This Autoimmune Drugmaker for $2.9 Billion in Cash. What It Means for the Stock. Barron's
Read full article →seeking-alphaMixed1h ago
Lilly to buy Merida Biosciences for up to $2.875B in cash
Read full article →investing-com1h ago
Lilly to acquire Merida Biosciences for up to $2.875 billion
By Investing.com
Read full article →Coverage Timeline
First report: investing-com · 31 Aug, 10:48|Full coverage: 4 · 34m|Window: 34m
Left-leaningCenterRight-leaning
